Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
Vanguard Portfolio Management LLC reports beneficial ownership of Alignment Healthcare Inc. common stock. It beneficially owns 11,874,585 shares, representing 5.74% of the outstanding common stock. Vanguard has sole voting power over 202,326 shares and sole dispositive power over 11,874,585 shares, with no shared voting or dispositive power.
The holdings reflect securities beneficially owned, or deemed beneficially owned, by Vanguard Portfolio Management LLC and specified Vanguard affiliates, including registered funds and other managed accounts. Vanguard entities have rights to dividends and sale proceeds on these securities, but no single other person’s interest exceeds 5% of the class.
Alignment Healthcare reported results for the quarter ended June 30, 2026, with total revenue of $1,335.6 million, up 31.6% year-over-year, and health plan membership of approximately 294,100, up 31.5%. The company stated that performance surpassed the high end of its guidance across key metrics.
Adjusted gross profit was $182.9 million, up 35.3%, and income from operations was $42.1 million. Medical benefits ratio based on adjusted gross profit was 86.3%, improving about 40 basis points year-over-year. Adjusted EBITDA was $68.1 million, reflecting a 5.1% margin, while net income increased to $36.6 million from $15.7 million.
For the third quarter of 2026, the company forecasts revenue between $1,300 million and $1,320 million and adjusted EBITDA between $20 million and $30 million. For full-year 2026, revenue guidance is $5,195 million to $5,225 million and adjusted EBITDA guidance is $145 million to $163 million, alongside higher expected membership and adjusted gross profit.
BlackRock, Inc. reports beneficial ownership of Alignment Healthcare, Inc. common stock on a passive Schedule 13G/A basis. BlackRock reports beneficial ownership of 18,719,986 shares of common stock, representing 9.1% of the outstanding class.
BlackRock has sole voting power over 18,431,099 shares and sole dispositive power over all 18,719,986 shares, with no shared voting or shared dispositive power. Various underlying clients have economic interests in these shares, but no single person is stated to hold more than five percent of Alignment Healthcare’s total outstanding common stock.
Alignment Healthcare, Inc. president Dawn Christine Maroney reported an option exercise and related stock sale. She exercised options to acquire 152,068 shares of common stock at $9.0600 per share and sold 177,068 shares in open-market transactions at a weighted-average price of $20.8281 per share under a Rule 10b5-1 trading plan adopted on 3/13/26, with individual sale prices ranging from $20.29 to $21.14. The exercised options, granted on 03/08/2022, vested 25% on each of the first four anniversaries of the grant date.
A Form 144 notice for ALHC covers a proposed sale of up to 177,068 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $3,753,841.60 and 206,733,823 shares outstanding. The shares include stock acquired via Exercise of Stock Options and RSU/PSU awards. It also lists prior 10b5-1 sales of 30,000 shares on May 15, 2026, for $482,567.00 and 30,000 shares on June 15, 2026, for $586,424.50.
Alignment Healthcare, Inc. CEO and director John E. Kao reported open-market sales of 298,000 shares of common stock on July 10, 2026. The shares were sold in multiple transactions at weighted-average prices of $19.8122 and $20.6471 per share under a Rule 10b5-1 trading plan adopted on November 21, 2025, and include sales from a trust for which Mr. Kao serves as trustee.
A selling holder has filed a notice to sell up to 596,000 shares of ALHC common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The proposed sale has an aggregate value of $12,533,880.00, with ALHC common stock listed on NASDAQ. ALHC had 206,733,823 shares of common stock outstanding as of this notice, which is a baseline figure, not the amount being sold. In the past three months, the same plan sold shares on three dates with specified share amounts and proceeds.
Hochradel Shane J. reported acquisition or exercise transactions in this Form 4 filing.
Alignment Healthcare, Inc. reported that Chief Operations Officer Shane J. Hochradel received an award of 87,719 restricted stock units, each representing the right to receive one share of common stock. These RSUs vest in roughly equal installments on March 13, 2027, 2028 and 2029, conditioned on his continued service. Following this compensation-related grant, his reported holdings from this award total 87,719 units.
Alignment Healthcare, Inc. executive Joseph S. Konowiecki, EVP of Corporate Affairs and a director, sold 25,000 shares of common stock in an open-market transaction at $24.00 per share. The sale was made under a Rule 10b5-1 trading plan adopted on 03/04/2026. After this transaction, he directly holds 1,103,816 shares, so the sale represents a relatively small portion of his overall stake.